Does SGLT2 inhibition protect the heart in type 2 diabetes?
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study looks at whether two types of diabetes medications—SGLT2 inhibitors and GLP-1 receptor agonists—help protect the heart in people with type 2 diabetes. It involves a first group that reviews past medical records, and a second group that will be monitored for 6 months after starting an SGLT2 inhibitor to see how their heart function changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (19 years or older for the first part, 50 or older for the heart-check part).
- You must have type 2 diabetes (not type 1 or diabetes caused by other conditions).
- You cannot have heart failure or serious heart conditions, especially for the heart-check part of the study.
- You must be starting a new diabetes medication—either an SGLT2 inhibitor (like empagliflozin) or a GLP-1 receptor agonist (like semaglutide), or another standard blood sugar-lowering drug (for the first part).
- If you are in the heart-check group, you must have at least one risk factor for heart problems, such as having diabetes for 5 years or longer, high blood pressure, or being overweight.
- You cannot be pregnant or have severe kidney disease (kidney function below a certain level).
- You must be willing to attend follow-up visits (if participating in the heart-check part).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
This study tests whether a diabetes medication called SGLT2 inhibitors can slow the buildup of plaque in heart arteries. Researchers will use special CT scans to track changes in your coronary arteries over time.
This Phase 4 trial studies an approach to help prevent heart problems in adults with type 2 diabetes who are at higher heart risk. It may help reduce future cardiovascular events by testing medications for safety and benefit in this group.
This study looks at how starting an SGLT2 inhibitor (a diabetes medicine) around the time of a heart attack affects heart outcomes and heart muscle changes over time. It may help you and your care team understand whether this timing is beneficial after a PCI procedure.
This study tests a type of diabetes medicine (an SGLT2 inhibitor) to see if it helps improve heart function in people with type 2 diabetes. It specifically looks at changes in the left atrium, a chamber of the heart, and may help protect your heart over time.
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
Hear when a new Cardiovascular Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.